{{short description|Australian bioentrepreneur (born 1981)}} {{Multiple issues| {{BLP sources|date=April 2015}} {{primarysources|date=January 2025}} }} {{Use dmy dates|date=April 2022}}
'''Martin Rogers''' (born 1981) is an Australian bioentrepreneur who has been associated since 2007 with a number of ASX-listed biotechnology companies, including Prima BioMed, which he led from 2007 to 2012.
== Background == Rogers attended the University of New South Wales between 1999 and 2004 where he gained a double degree in chemical engineering and computer science. Between 2004 and 2007 he engaged in a number of entrepreneurial pursuits as well as worked at Macquarie Bank.<ref>{{Cite web| title=Company announcement - Appointment of Director | url=http://www.asx.com.au/asxpdf/20071016/pdf/3154n4hhtxgzr8.pdf | archive-url=https://web.archive.org/web/20160304053136/http://www.asx.com.au/asxpdf/20071016/pdf/3154n4hhtxgzr8.pdf | archive-date=2016-03-04}}</ref>
== Prima BioMed == Rogers was part of an investor group that effectively took control of Prima BioMed in late 2007, when he was appointed a director. At that time Prima had Phase IIa data for its CVac cancer vaccine product, but did not have the funds to progress further. Under Rogers' leadership Prima achievements included:
* Raised approx. A$82m in new capital: Rogers started with a 1-for-2 rights issue in October 2007 (A$2.0m)<ref>{{cite news|title=Company announcement - non-renounceable rights issue|url=http://www.asx.com.au/asxpdf/20071022/pdf/3157vzg11k06n4.pdf|access-date=23 July 2015|publisher=Prima BioMed|date=23 October 2007}}</ref> and followed with Share Purchase Plans in December 2008<ref>{{cite news|title=Company announcement - Completion of Share Purchase Plan|url=http://www.asx.com.au/asxpdf/20090107/pdf/31fh3j97235tfc.pdf|access-date=23 July 2015|publisher=Prima BioMed|date=9 January 2009}}</ref> and June 2009<ref>{{cite news|title=Company announcement - Completion of Share Purchase Plan|url=http://www.asx.com.au/asxpdf/20090629/pdf/31j9h78bbbyh8d.pdf|access-date=23 July 2015|publisher=Prima BioMed|date=29 June 2009}}</ref> (each approx A$0.2m) and a share placement in June 2009 (A$1.5m)<ref>{{cite news|title=Prima BioMed - Notice of Extraordinary General Meeting|url=http://www.asx.com.au/asxpdf/20090522/pdf/31hqf36nvk13x1.pdf|access-date=23 July 2015|publisher=Prima BioMed|date=25 May 2009}}</ref> before securing an equity funding line which allowed A$14.7m to be raised between July 2011 and March 2011. From late 2009 capital raising became easier. A third Share Purchase Plan in December 2009 raised A$13.7m<ref>{{cite news|title=Company announcement - Completion of Share Purchase Plan|url=http://www.asx.com.au/asxpdf/20091201/pdf/31mh0k3t87lmjx.pdf|access-date=23 July 2015|publisher=Prima BioMed|date=1 December 2009}}</ref> while a placement and associated Share Purchase Plan in June 2011 raised A$41.4m.<ref>{{cite news|title=Company announcement - Prima BioMed raises $20 million in Share Purchase Plan|url=http://www.asx.com.au/asxpdf/20110628/pdf/41zg7ltyp1vxnp.pdf|access-date=23 July 2015|publisher=Prima BioMed|date=28 June 2011}}</ref> Between 2009 and 2012 the exercise of options brought in another A$8.4m (A$1.3m in 2009/10,<ref>{{cite web|title=Prima BioMed 2010 Annual Report|url=http://www.primabiomed.com.au/investor/annual_reports_pdf/2010_Annuals.pdf|publisher=Prima BioMed|access-date=23 July 2015}}</ref> A$5.1m in 2010/11<ref>{{cite web|title=Prima BioMed 2011 Annual Report|url=http://www.primabiomed.com.au/investor/annual_reports_pdf/2011_annuals.pdf|publisher=Prima BioMed|access-date=23 July 2015}}</ref> and A$2.0m in 2011/12<ref>{{cite web|title=Prima BioMed 2012 Annual Report|url=http://www.primabiomed.com.au/investor/annual_reports_pdf/2012_annuals.pdf|publisher=Prima BioMed|access-date=23 July 2015}}</ref>). * Experienced an increase in its share price: Prima stock re-rated 19-fold between December 2007 and April 2011, creating a company with a market value of ~A$300m.<ref>{{cite web|title=Rhinomed (RNO) - Breathtaking early stage opportunity|url=http://www.rhinomedshop.com/media/wysiwyg/230514_Baillieu_Holst_Research.pdf|website=Rhinomed|publisher=Baillieu Holst|access-date=23 July 2015}}</ref>
Prima announced in May 2012 that Rogers would be stepping down as CEO.<ref>{{Cite web| title=Prima Biomed announces changes to the board and senior management | url=http://www.asx.com.au/asxpdf/20120524/pdf/426fwpvk9p6xsb.pdf | archive-url=https://web.archive.org/web/20150723085600/http://www.asx.com.au/asxpdf/20120524/pdf/426fwpvk9p6xsb.pdf | archive-date=2015-07-23}}</ref> He left Prima at the end of August 2012. By the end of tenure Prima had made it into the S&P/ASX 300.<ref>{{Cite web|url=http://www.smartcompany.com.au/leadership/37223-prima-biomed-time-to-change-leader.html#|title = Prima BioMed: Time to change leader|date = 24 May 2012}}</ref>
== Since Prima Biomed == Since 2012 Rogers has been involved at board level in a number of ASX-listed biotech companies, including Cellmid (ASX: CDY) between September 2012<ref>{{Cite web| title=Appointment of director | url=http://www.asx.com.au/asxpdf/20120919/pdf/428t55878z23cs.pdf | archive-url=https://web.archive.org/web/20150723081420/http://www.asx.com.au/asxpdf/20120919/pdf/428t55878z23cs.pdf | archive-date=2015-07-23}}</ref> and June 2015;<ref>{{Cite web| title=Appointment and resignation of directors | url=http://www.asx.com.au/asxpdf/20150526/pdf/42ysxlscqdmj7q.pdf | archive-url=https://web.archive.org/web/20150723125822/http://www.asx.com.au/asxpdf/20150526/pdf/42ysxlscqdmj7q.pdf | archive-date=2015-07-23}}</ref> Rhinomed (ASX: RNO), since September 2012;<ref>{{Cite web| title=Board restructure supports transition to commercial medical technology firm | url=http://www.asx.com.au/asxpdf/20120903/pdf/428gd108fszz38.pdf | archive-url=https://web.archive.org/web/20150723085319/http://www.asx.com.au/asxpdf/20120903/pdf/428gd108fszz38.pdf | archive-date=2015-07-23}}</ref> OncoSil Medical (ASX: OSL) since April 2013;<ref>{{Cite web| title=Appointment of Martin Rogers & executive package capital raising | url=http://www.asx.com.au/asxpdf/20130403/pdf/42f0v52ty3fcm2.pdf | archive-url=https://web.archive.org/web/20150723085419/http://www.asx.com.au/asxpdf/20130403/pdf/42f0v52ty3fcm2.pdf | archive-date=2015-07-23}}</ref> and Actinogen (ASX: ACW), since September 2014.<ref>{{Cite web| title=Proposed Board Changes: Appointment of Dr Jason Loveridge | url=http://www.asx.com.au/asxpdf/20140827/pdf/42rs6t46n69817.pdf | archive-url=https://web.archive.org/web/20150723084156/http://www.asx.com.au/asxpdf/20140827/pdf/42rs6t46n69817.pdf | archive-date=2015-07-23}}</ref>
In 2018, Martin Rogers, of KTM Ventures, co-invested with Mike Tilley to purchase a 30% stake in cryptocurrency exchange Independent Reserve.<ref>{{Cite web |date=2018-03-14 |title=Mike Tilley backs cryptocurrency exchange Independent Reserve |url=https://www.afr.com/chanticleer/mike-tilley-backs-cryptocurrency-exchange-independent-reserve-20180314-h0xftq |access-date=2023-10-30 |website=Australian Financial Review |language=en}}</ref><ref>{{Cite web |date=2022-11-23 |title=Forget the carnage; insiders are thriving in crypto |url=https://www.afr.com/wealth/investing/forget-the-carnage-insiders-are-thriving-in-crypto-20221123-p5c0k0 |access-date=2023-10-30 |website=Australian Financial Review |language=en}}</ref>
==References== {{reflist}}
{{DEFAULTSORT:Rogers, Martin}} Category:Australian business executives Category:1981 births Category:Living people